This wiki has undergone a migration to Confluence found Here
<meta name="googlebot" content="noindex">

Difference between revisions of "BiologicallyDerivedProduct FHIR Resource Proposal"

From HL7Wiki
Jump to navigation Jump to search
Line 114: Line 114:
 
Reference to resources is really only relevant at the "same or higher level" (Bo – fix this wording)
 
Reference to resources is really only relevant at the "same or higher level" (Bo – fix this wording)
 
  -->
 
  -->
 +
ProcedureRequest
 +
Patient
 +
Practitioner
 +
Substance
  
 
==Timelines==
 
==Timelines==

Revision as of 22:52, 9 September 2017



BiologicallyDerivedProduct

Owning committee name

Patient Care

Committee Approval Date:

Please enter the date that the committee approved this Resource proposal

Contributing or Reviewing Work Groups

  • Orders and Observations
  • Pharmacy

FHIR Resource Development Project Insight ID

Scope of coverage

A material substance originating from a biological entity intended to be transplanted or infused into another (possibly the same) biological entity.

Examples include:

  • hematopoietic stem cells (bone marrow, peripheral blood, or cord blood extraction)
  • blood (whole, extracted cells, plasma, etc)
  • organs
  • tissues (porcine valves, skin, bovine cardiac tissue, etc.)
  • manipulated cells (e.g. CAR T-cells)

RIM scope

Resource appropriateness

Organs, tissues, and fluids obtained from one biological entity (person or animal) for the purpose of infusion, transplantation or grafting to another biological entity are neither Specimens ("used for diagnostic and environmental testing") nor Devices ("an instance or a type of a manufactured item"). Furthermore, there is established a relationship between two entities, the donor and the recipient.

Expected implementations

Content sources

  • Patient undergoes hematopoetic cell transplantation (HCT) using autologous BiologicallyDerivedProduct
  • Patient undergoes HCT using HLA-matched BiologicallyDerivedProduct from another person
  • Patient receives post-HCT infusion of donor t-cells
  • Patient receives blood (BiologicallyDerivedProduct) transfusion
  • Patient receives HLA-matched platelets (BiologicallyDerivedProduct)
  • Patient receives heart transplant
  • Patient undergoes cardiac surgery receiving pig heart valve

Resource Relationships

ProcedureRequest Patient Practitioner Substance

Timelines

gForge Users

When Resource Proposal Is Complete

When you have completed your proposal, please send an email to FMGcontact@HL7.org

FMG Notes